TrialNature cancer2025

Regorafenib plus avelumab in advanced gastroenteropancreatic neuroendocrine neoplasms: a phase 2 trial and correlative analysis.

Sophie Cousin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.